Last updated: May 30, 2026

PHENERGAN VC W/ CODEINE market dynamics and financial trajectory (sales, pricing, exclusivity, and generic/biosimilar risk)

PHENERGAN VC W/ CODEINE is a cough-and-cold combination product that pairs promethazine (antihistamine/sedating antitussive adjunct) with codeine (opioid antitussive) for symptomatic relief. Market performance is driven by (1) the US opioid policy environment, (2) payer and formulary restrictions on codeine-containing cough products, (3) availability of therapeutically substitutable non-opioid cough/cold options, and (4) FDA and state enforcement affecting prescribing and dispensing. The financial trajectory typically follows a pattern seen with older, low-acquisition-cost combination NDCs: peak utilization is concentrated in the early branded lifecycle, then compresses as pricing pressure intensifies and generics expand, while opioid-risk scrutiny increasingly caps volume and reimbursable use.

Bottom line: PHENERGAN VC W/ CODEINE’s financial trajectory is likely to be volume-constrained and payer-constrained rather than innovation-driven, with long-run economics dominated by generic substitution and regulatory headwinds surrounding codeine cough products.

How do opioid policy and FDA enforcement affect sales of codeine cough syrup combinations?

Featured snippet: Codeine cough products face demand friction from opioid prescribing limits, FDA safety communications, and state-level enforcement targeting opioid misuse. That reduces total dispensed volume and shifts prescribers toward non-opioid alternatives.

What specific regulatory pressures hit codeine-containing cough products

Key demand drivers for codeine antitussives include:

Prescriber deterrence tied to opioid abuse, misuse, and diversion risk.
Safer prescribing messaging and tighter clinical governance within integrated delivery networks.
State substitution and enforcement patterns that target opioid dispensing for cough/cold indications.
Pharmacy-level utilization management (limited quantities, prior authorizations in some formularies, and selective stocking).

How this changes commercial mix

Share shifts from opioid-containing cough regimens to non-opioid cough suppressants (where clinically acceptable) and antihistamine-only symptomatic regimens.
Physicians who previously used codeine-based antitussives for short-term cough increasingly choose alternatives when patient risk factors (sedation risk, age, sleep apnea, concomitant CNS depressants) are present.

Net effect on financial trajectory

Gross revenue growth is constrained even when unit prices remain stable.
Over time, ASP compression and volume declines dominate, especially where generics already exist and payer restrictions further reduce utilization.

What market dynamics determine revenue for promethazine plus codeine cough-and-cold drugs?

Featured snippet: Revenue is shaped by competitive substitution, formulary access, and the opioid-risk environment that impacts prescribing and dispensing.

Competitive and substitution forces

Therapeutic substitution: Many patients and prescribers shift to non-opioid cough solutions and multi-symptom OTC approaches.
Formulary tiering: Codeine combinations often land in lower-preferred tiers or face coverage controls.
Generic intensity: Once branded exclusivity ends, pricing and margin compress rapidly as multiple generic manufacturers compete.

Inventory and distribution

Codeine products are sensitive to distributor and pharmacy behavior:
- reduced automatic ordering,
- tighter inventory turns,
- higher compliance friction for dispensing.

Channel dynamics

Commercial pull depends on how often codes are reimbursed in payer policies.
Retail pharmacy fulfillment patterns matter more than specialty channels, since cough/cold care is generally managed in primary care and urgent settings.

How strong is the patent estate for PHENERGAN VC W/ CODEINE, and when does exclusivity end?

Featured snippet: Combination cough-and-cold products with older actives generally rely on older compound, formulation, or method-of-use protection. For many such products, the practical IP posture is typically dominated by legacy patents that expire years earlier, leaving the market to generic competition and any remaining formulation/process patents.

Patent landscape mechanics for combination OTC-adjacent products

For promethazine plus codeine combinations, market exclusivity is usually fragmented across:

composition of matter (rarely still active for long-marketed drugs),
formulation (stabilizers, dosing, taste-masking, delivery parameters),
manufacturing process (control of impurities and stability),
method-of-use (often limited for non-specific symptomatic indications).

Exclusivity timeline impact

When exclusivity expires, the financial trajectory typically transitions to:

multi-source competition (ASP drops),
regional price dispersion based on formulary and wholesaler contracting,
faster channel turnover for generics.

What “remaining protection” tends to look like

Even if broad exclusivity ends, the most persistent legal friction in low-innovation symptom drugs can come from:

late-expiring formulation/process claims,
Orange Book listing-driven Paragraph IV litigation,
line-extension patents on specific NDC strengths or packaging.

What generic entry risks exist for promethazine-codeine combination cough syrups?

Featured snippet: Generic entry risk is primarily driven by Orange Book status, remaining formulation/process patents, and whether ANDA challengers file Paragraph IV certifications on listed patents.

Paragraph IV and ANDA mechanics

For small-molecule combination liquids:

ANDAs typically seek to match active ingredients and strength plus pharmaceutical equivalence.
If the branded product lists patents, ANDA filers can challenge via Paragraph IV.

Settlement-driven timelines

A typical generic entry schedule looks like:

Paragraph IV filing triggers a 30-month stay if applicable.
If litigation resolves via settlement, generic launch can occur earlier than the theoretical end of the stay.
If patents are upheld, launch shifts to patent expiry or resolution.

Financial impact of generic launches

Branded revenue declines sharply after first generic launches.
ASP keeps trending down as additional entrants appear.
Margin shifts from manufacturer-operated promotional spending toward contracted wholesale and pharmacy penetration.

What is the Orange Book status of PHENERGAN VC W/ CODEINE, and how many patents cover it?

Featured snippet: Orange Book status determines how many listed patents constrain generic approval. For older combination cough products, the number of listed patents is often limited, and many are already expired, leaving mostly late-expiring formulation/process protections.

How to interpret Orange Book listings for market forecasting

Listed drug products and dosage forms matter: liquid strength and packaging can have separate patent sets.
Patent types matter: method-of-use and formulation can delay generics if claims are valid and narrow but remaining.

Market forecasting linkage

More listed patents typically mean longer periods of legal friction and slower price erosion.
Fewer valid/remaining patents means faster multi-source generic saturation.

How does PHENERGAN VC W/ CODEINE compare with non-opioid cough/cold alternatives on pricing and access?

Featured snippet: Non-opioid alternatives generally have easier payer access and avoid opioid prescribing friction, so they gain share even when unit cost is higher.

Payer access

Opioid-containing products are more likely to face:
- coverage limits,
- utilization management,
- tighter clinical edit controls.
Non-opioid regimens generally face fewer policy barriers.

Pricing dynamics

Codeine combinations can stay cheap per dose, but total reimbursed utilization can fall.
Non-opioid products can be costlier unit-wise but can still win economically through:
- fewer denials,
- higher dispensed volume.

Result for financial trajectory

Even if the branded product’s net price holds briefly, the long-run P&L trends toward lower volume.
Generics can lose share if payers steer prescribing toward non-opioids.

What formulation and manufacturing IP issues could block generic versions?

Featured snippet: Liquid combination products are vulnerable to formulation/process differences that affect stability, impurities, and equivalence specifications. Those can drive secondary patent disputes.

Formulation hotspots

Stability under storage conditions (temperature, light, and oxygen exposure).
Control of degradation products.
Consistency of viscosity and dosing uniformity.

Manufacturing and impurity control

Batch release criteria and impurity profiles can support method/process claims.
If the branded holder has specific validated controls, ANDA applicants may face additional bridging or comparability hurdles.

Commercial consequence

If formulation/process patents are asserted:

generic launch can be delayed,
price erosion slows,
branded revenue can remain higher longer but usually still trends down over time.

What patent litigation affects promethazine-codeine combination cough products?

Featured snippet: Litigation risk is typically limited to disputes over Orange Book patents for specific NDCs rather than broad claims over the core active ingredients.

Common litigation patterns

Patent infringement suits tied to Orange Book-listed formulation/process claims.
Secondary claims on impurity control, stability, or manufacturing steps.
Settlement-based “carve-outs” that define launch dates by NDC strength or packaging.

Why litigation matters to finance

Even if the drug is no longer under strong broad exclusivity, litigation can create temporary pricing support.
Conversely, fast adverse outcomes compress revenue quickly.

What FDA regulatory status and labeling trends influence utilization for codeine cough products?

Featured snippet: Labeling and safety communications that emphasize opioid risk and contraindications reduce eligible patient populations and influence prescribing patterns.

Labeling constraints that affect utilization

Typical utilization reducers for opioid-containing cough/cold products include:

age restrictions and pediatric risk warnings,
CNS depressant interaction warnings (sedation risk),
contraindications in certain respiratory conditions,
guidance that pushes clinicians toward risk-balanced prescribing.

Operational effect

Lower prescribing eligibility means lower dispensed volume across retail.

Commercial landscape: which companies typically compete for promethazine-codeine cough syrup share?

Featured snippet: The market usually transitions from branded-only to multi-source generic competition, then may see further share shifts to non-opioid alternatives.

How to evaluate competitor pressure

Generic number of entrants for the same NDC strength.
Regional contracting with wholesalers.
Pharmacy stocking patterns and preferred formulary status.

Financial implication

More entrants drive ASP down and can reduce the branded product’s remaining unit share even without major legal barriers.

Key takeaways: PHENERGAN VC W/ CODEINE market and financial outlook

Demand is policy- and risk-constrained because the product contains codeine.
The long-run revenue trajectory is typically volume erosion plus ASP compression as generic competition expands and payers steer prescribing away from opioid-containing cough options.
Patent estate impact, when relevant, is usually limited to remaining formulation/process protections and Orange Book-listed claims that can delay generic entry by months to a few years.
The dominant financial drivers are formulary access, prescribing behavior, and regulatory enforcement, not new clinical differentiation.

FAQs

1) What drives short-term sales spikes for codeine cough syrup combinations?
Retail and urgent-care demand cycles can create short-lived volume increases, but opioid-risk controls and payer edits usually cap sustained growth.

2) How do opioid safety communications change pharmacy dispensing patterns?
They increase prescriber hesitation and reduce eligible patient populations, leading to lower dispensed counts even when unit prices are stable.

3) Do formulation or manufacturing patents matter after generic approval pathways begin?
They matter when they are Orange Book-listed and tied to specific NDCs, because they can trigger Paragraph IV disputes or delayed launches.

4) Does settlement with ANDA filers usually affect revenue materially?
Yes. Settlements often determine launch timing by NDC and can extend brand pricing headroom until the agreed entry date.

5) Why do non-opioid cough/cold products often gain share even against low-cost generics?
Coverage and prescribing friction for opioid-containing products can outweigh unit price differences.

References

No sources were cited because no verifiable, drug-specific Orange Book, patent, FDA labeling, litigation, or financial data for “PHENERGAN VC W/ CODEINE” was provided in the prompt.

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	1
DailyMed Link:	PHENERGAN VC W/ CODEINE at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	PHENERGAN VC W/ CODEINE	codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride	SYRUP;ORAL	008306-005	Apr 2, 1984		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

AI Deep Research

Questions you can ask:

Summary for PHENERGAN VC W/ CODEINE